Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review.

@article{Ruh2006SwitchingAA,
  title={Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review.},
  author={H. Ruh{\'e} and J. Huyser and J. Swinkels and A. Schene},
  journal={The Journal of clinical psychiatry},
  year={2006},
  volume={67 12},
  pages={
          1836-55
        }
}
OBJECTIVE Selective serotonin reuptake inhibitors (SSRIs) are frequently used as a first antidepressant for major depressive disorder but have response rates of 50% to 60% in daily practice. For patients with insufficient response to SSRIs, switching is often applied. This article aims to systematically review the evidence for switching pharmacotherapy after a first SSRI. DATA SOURCES A systematic literature search (updated until Feb. 10, 2005) in MEDLINE, EMBASE, CINAHL, and PsychINFO (all… Expand
View on PubMed
pure.uva.nl
213 Citations
Highly Influential Citations
10
Background Citations
58
Methods Citations
8
Results Citations
17

213 Citations

Citation Type

Citation Type

Strategies for switching antidepressants to achieve maximum efficacy adolescents.
  • J. Jefferson
  • Medicine, Psychology
  • The Journal of clinical psychiatry
  • 2008
TLDR
If a patient with major depressive disorder has not responded after an adequate trial of an antidepressant medication, switching to another antidepressant of the same class or a different class may help, and the choice should be made based on the patient, the patient's illness, the medications involved, and clinical judgment. Expand
Pharmacologic approaches to treatment resistant depression: Evidences and personal experience.
TLDR
Evidence supports the usefulness of switching from SSRI to venlafaxine, but data on combination strategy are controversial regarding TCA-SSRI combination and bupropion-SSri combination and positive regard mirtazapine (or its analogue mianserine) combination with ADs of different classes. Expand
The use of sequential pharmacotherapy for the treatment of acute major depression: a scoping review
TLDR
This scoping review synthesizes and discusses available evidence for sequential pharmacotherapy for MDD and recommends studies that include an assessment of moderators and mediators (‘mechanism’) of antidepressant response to provide more personalized treatment. Expand
Sertraline treatment of patients with major depressive disorder who failed initial treatment with paroxetine or fluvoxamine
TLDR
Preliminary data suggest that the switching strategy from paroxetine or fluvoxamine to sertraline might be effective and well-tolerated in patients with non-remitted or treatment-intolerant major depressive disorder. Expand
Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder.
TLDR
Patterns of antidepressant drug use and depression-related and all-cause medical costs for patients who switched therapy between 2 drug classes, selective serotonin reuptake inhibitors (SSRIs) and the selective norepinephrine reptake inhibitor (SNRI) venlafaxine are explored. Expand
Citalopram versus desipramine in treatment resistant depression: Effect of continuation or switching strategies. A randomized open study
  • D. Souery, A. Serretti, +8 authors J. Mendlewicz
  • Medicine
  • The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry
  • 2011
TLDR
This study supports the thesis that switching from an SSRI to a TCA (and vice versa) in non-responders to a 4-week trial of an SSri/TCA is not associated with improved response, and the result goes in the opposite direction to that predicted by current guidelines. Expand
Early Switching Strategies in Antidepressant Non-Responders: Current Evidence and Future Research Directions
TLDR
There is reasonable evidence to recommend earlier assessment for improvement at 2–4 weeks after starting an antidepressant, and taking into account other patient and clinical factors, a change in management can be considered. Expand
Switching to duloxetine from selective serotonin reuptake inhibitors in non- or partial responders: Results from a Spanish sample
TLDR
In a population of Spanish SSRI non- and partial responders, switch to duloxetine was associated with significant improvement in emotional and painful symptoms of depression, and was well tolerated and safe during both phases. Expand
Pharmacological interventions for treatment-resistant depression in adults.
TLDR
There was no evidence of a difference in depression severity when current treatment was switched to mianserin, and eight studies augmented current antidepressant treatment with a non-antidepressant or an antipsychotic (cariprazine; olanzapine; quetiapine); or ziprasidone (2 studies). Expand
Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis
TLDR
Escitalopram is associated with a better efficacy and tolerability profile than SNRIs (duloxetine and venlafaxine) when used as a second step treatment in patients with MDD. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 148 REFERENCES
Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current "next-step" practices.
TLDR
Clinicians select different next-step strategies when patients are nonresponders versus when patients is partial responders or relapsers, and switching to a non-SSRI agent was the most frequently chosen option for non responders to an adequate trial of SSRI therapy. Expand
Dose escalation for insufficient response to standard-dose selective serotonin reuptake inhibitors in major depressive disorder
TLDR
Dose escalation of SSRIs is equivocally supported by evidence of randomised controlled trials; methodological difficulties in the studies may account for this lack of evidence. Expand
Strategies for Managing Depression Refractory to Selective Serotonin Reuptake Inhibitor Treatment: A Survey of Clinicians
TLDR
Clinicians in this sample often followed strategies different from those recommended in the literature, including bupropion as a first-choice augmenter, whereas less experienced ones showed a slight preference for lithium. Expand
Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial.
TLDR
The SSRI antidepressants paroxetine, fluoxettine, and sertraline were similar in effectiveness for depressive symptoms as well as multiple domains of health-related quality of life over the entire 9 months of this trial. Expand
Switching to bupropion in fluoxetine-resistant major depressive disorder.
  • M. Fava, G. Papakostas, +4 authors P. McGrath
  • Medicine
  • Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists
  • 2003
TLDR
Bupropion SR should be considered as a potential treatment for patients who remain depressed despite treatment with SSRIs, and approximately 60% of patients with MDD resistant to a prospective trial of fluoxetine experienced a full or partial response to bupropion SR. Expand
Meta-analytical studies on new antidepressants.
TLDR
A systematic search found 108 meta-analyses of the use of antidepressants in depressive disorders of uneven quality and confidence, which limits the confidence in many of the results. Expand
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
TLDR
Abrupt interruption of antidepressant therapy for 5-8 days was associated with the emergence of new somatic and psychological symptoms in patients treated with paroxetine and to a lesser degree sertraline, with few symptoms seen with fluoxetines. Expand
Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study
TLDR
It is suggested that venlafaxine extended release may be more effective than the conventional antidepressants used in this study when treating depressed patients who do not tolerate or respond adequately to treatment with a conventional antidepressant. Expand
Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline.
TLDR
Findings indicate that fluoxetine and sertraline, two widely used SSRIs, are not interchangeable and patients who either have had trouble tolerating or have not responded to sertRALine may do well on fluoxettine treatment. Expand
Combining antidepressants for treatment-resistant depression: a review.
TLDR
There is limited evidence, mostly in uncontrolled studies, supporting the efficacy of combination antidepressant treatment, and further randomized controlled trials with larger sample sizes are required to demonstrate the efficacy. Expand
...
1
2
3
4
5
...